BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 8298644)

  • 21. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
    Schulz S; Becker KF; Braungart E; Reichmuth C; Klamt B; Becker I; Atkinson M; Gessler M; Höfler H
    J Pathol; 2000 Jun; 191(2):162-9. PubMed ID: 10861576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
    Pelletier J; Bruening W; Li FP; Haber DA; Glaser T; Housman DE
    Nature; 1991 Oct; 353(6343):431-4. PubMed ID: 1654525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytogenetic findings in Wilms' tumour: a single institute study.
    MdZin R; Murch A; Charles A
    Pathology; 2010 Dec; 42(7):643-9. PubMed ID: 21080873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
    Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
    J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
    Roberts DJ; Haber D; Sklar J; Crum CP
    Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonality and loss of heterozygosity of WT genes are early events in the pathogenesis of nephroblastomas.
    Guertl B; Ratschek M; Harms D; Jaenig U; Leuschner I; Poremba C; Hoefler G
    Hum Pathol; 2003 Mar; 34(3):278-81. PubMed ID: 12673563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetics of Wilms' tumor.
    Coppes MJ; Egeler RM
    Semin Urol Oncol; 1999 Feb; 17(1):2-10. PubMed ID: 10073400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity at 7p in Wilms' tumour development.
    Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
    Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and cellular biology of Wilms' tumour.
    Maitland NJ; Brown KW; Poirier V; Shaw AP; Williams J
    Anticancer Res; 1989; 9(5):1417-26. PubMed ID: 2556071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
    Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
    Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A point mutation within exon 5 of the WT1 gene of a sporadic unilateral Wilms' tumor alters gene function.
    Guan LS; Liu JJ; Xu YH; Wang ZY
    Cancer Res; 1998 Sep; 58(18):4180-4. PubMed ID: 9751632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
    Fukuzawa R; Heathcott RW; More HE; Reeve AE
    J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional regulation by the Wilms' tumour suppressor protein WT1.
    Wagner KJ; Roberts SG
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
    Morrison DJ; English MA; Licht JD
    Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular genetics of Wilms' tumor].
    Papezová M; Mares J; Goetz P
    Cas Lek Cesk; 2001 Jun; 140(11):323-7. PubMed ID: 11431850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
    Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
    Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural rearrangements of the WT1 gene in Wilms' tumour cells.
    Cowell JK; Wadey RB; Haber DA; Call KM; Housman DE; Pritchard J
    Oncogene; 1991 Apr; 6(4):595-9. PubMed ID: 1851548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.